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Letter to the Editor
Low macrolide resistance in Streptococcus pyogenes in
Southern Argentina
Sir,
In recent years, macrolide resistance in Streptococcus pyo-
genes has increased, with great variability over different areas
[1–4] and has been associated with increased macrolide use
[5,6]. Two main mechanisms for macrolide resistance have
been identified: target site modification and drug efflux [7,8].
In Argentina, although prevalence of erythromycin resis-
tance in S. pyogenes is still low, it has increased significantly
in recent years according to data from densely populated
areas.
The aim of this study was to evaluate the dynamics of
macrolide resistance in S. pyogenes in Bariloche, a small

























ermA, ermB, ermC, ermTR and mefA in S. pyogenes have
been previously described [10].
Susceptibility testing showed that 26 of 1068 (2.4%) S.
pyogenes isolates were resistant to erythromycin (MICs 2 to
256 mg/l; Table 1). All resistant strains came from outpa-
tients. Resistance rates in adults were 3.5% and in children,
2.1% (difference not statistically significant; χ2 = 0.867,
P= 0.35).
All three different macrolide resistance phenotypes were
found: 22 strains (84.6%) expressed the M phenotype, two
(7.7%) expressed the constitutive MLSb phenotype and two
(7.7%) the inducible MLSb phenotype. PCR-based detection
of resistance genes showed that all strains showing the M
phenotype harboured the mef A gene while erm TR genes
were found in both strains expressing the inducible MLSB
phenotype; erm B genes were present in strains with con-
0
do determine the phenotypes and genetic mechanisms of
acrolide-lincosamide resistance.
A total of 1068 consecutive S. pyogenes strains were col-
ected during 2000–2003 in the clinical microbiology labo-
atories of the three main medical institutions of Bariloche.
stitutive MLSB phenotype (Table 1). The M phenotype was
the predominant resistance phenotype as show previously by
other investigators in Argentina and South America [3,4]. All
S. pyogenes studied were susceptible to penicillin.
Resistance values rose significantly from 0.59% during
2our hundred and forty-four strains were obtained from the
ity’s public hospital and 624 originated from two private
ospitals. Of these, 78.6% of isolates were obtained from
hildren (2–16 years old) and 21.4% from adults. Most iso-
ates (1022) were recovered from throat swabs but 44 came
the first year of the study to 5.02% at the end (χ = 5.35,
P= 0.02). Furthermore, most of the resistant strains isolated
during 2003, the last year of study, originated from private in-
stitutions where resistance was 6.57%, compared with 1.61%













Internatrom other clinical samples.
Strains were identified using standard procedures: 
aemolysis, bacitracin sensitivity, and pyrrolidonyl arylami-
ase activity.
Macrolide-resistant strains were initially identified by the
isk diffusion method on Mueller–Hinton agar supplemented
ith 5% defibrinated sheep blood (Biomerieux), using a
5g erythromycin disks and 2g clindamycin disks as
ecommended in the NCCLS guidelines. Penicillin sensi-
ivity was also tested for all strains using an agar diffusion
ethod and 10 units disks. The resistant phenotypes of ery-
hromycin resistant strains were determined by the double-
isk test using erythromycin and clindamycin disks sepa-
ated by 15–20 mm [9]. The MICs of erythromycin and clin-
amycin were determined for all the macrolide resistant iso-
ates by the Etest method (Biodisk AB, Solna, Sweden).
PCR-based detection of resistance genes was performed as
escribed by Martinez et al. [4]. The primers used to detect
924-8579/$ – see front matter © 2005 Published by Elsevier B.V. and the
oi:10.1016/j.ijantimicag.2005.01.010ere not statistically significant (χ2 = 3.42, P= 0.06), the in-
idence of resistance in isolates from private hospitals seems
o be increasing at a greater rate than that in the population
ttending the public hospital. While public institutions are
ttended by social classes with low or no income, private
able 1
istribution of MICs of macrolides, phenotypes and genotypes for 26 resis-
ant Streptococcus pyogenes isolates
henotype Genotype n Antimicrobial agent MIC (mg/l)
Range
mefA 22 Erythromycin 2–24
Clindamycin 0.019–0.125
MLSb ermTR 2 Erythromycin 2–16
Clindamycin 0.094–0.25
MLSb ermB 2 Erythromycin >256
Clindamycin >256
ional Society of Chemotherapy.
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Table 2
Annual distribution of erythromycin resistance in private and public health institutions
Year Private Public Global
Total Resistant strains Total Resistant strains Total Resistant strains
n n (%) n n (%) n n (%)
2000 – – 169 1 (0.59) 169 1 (0.59)
2001 141 0 (0) 82 0 (0) 223 0 (0)
2002 209 4 (1.91) 69 1 (1.45) 278 5 (1.80)
2003 274 18 (6.57) 124 2 (1.61) 398 20 (5.02)
hospitals are attended by a wealthier population. The former
is typically provided of antibiotics by the institution, which
includes a limited use of macrolides. The latter instead, prob-
ably consume larger amounts of macrolides especially after
the recent introduction of new types of macrolides with im-
proved pharmacokinetic properties.
In conclusion, macrolide resistance in S. pyogenes in
Bariloche is still low compared with other geographical ar-
eas of Argentina with a higher population density, and many
other countries. Nevertheless, increase in resistance was sta-
tistically significant during the study period. This dynamic
pattern and the abundant evidence on increasing resistance in
streptococci related to increase macrolide use, suggest that
surveillance should be continued and that a careful usage of
macrolide antibiotics would be advisable.
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